TARS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tarsus Pharmaceuticals Inc (TARS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive growth prospects and analyst confidence, the current technical indicators suggest a bearish trend, and the stock is oversold. Additionally, insider selling activity and a lack of recent positive news or catalysts make it prudent to wait for a more favorable entry point.
The MACD histogram is -1.016, indicating a bearish trend. RSI is at 13.334, signaling the stock is oversold. Moving averages are converging, and the stock is trading near its support level (S1: 61.904). The pre-market price is $61.01, slightly above the support level but below the pivot point (67.447).
Analysts have raised price targets significantly, with targets ranging from $90 to $105, citing strong sales guidance and growth potential. Hedge funds are buying, with a 987.14% increase in buying activity over the last quarter.
Insiders are selling heavily, with a 1503.33% increase in selling activity over the last month. The stock has a 40% chance of declining in the short term, with a potential -9.26% drop over the next month. No recent news or congress trading data to act as a positive catalyst.
In Q4 2025, revenue increased by 128.39% YoY to $151.67M, but net income dropped by -63.77% YoY to -$8.37M. EPS also declined by -66.67% YoY to -0.2. Gross margin improved slightly to 92.8%, up 0.24% YoY.
Analysts are optimistic, with multiple firms raising price targets (e.g., Mizuho to $101, Oppenheimer to $105, Guggenheim to $90). Analysts highlight strong sales guidance, new-patient demand, and favorable risk/reward dynamics.
